Table 3 Systemic Therapy
From: Radiotherapy for inferior vena cava tumor thrombus in patients with hepatocellular carcinoma
No. of patients (%) | |||
|---|---|---|---|
Systemic therapy | Pre-R/T | During RT | Post-R/T |
Total | 12 (28.6) | 24 (57.1) | 21 (50.0) |
Sorafenib | 12 (28.6) | 17 (40.5) | 16 (38.1) |
Nivolumab | 1 (2.4) | 2 (4.8) | 2 (4.8) |
Thalidomide | 0 (0.0) | 4 (9.5) | 1 (2.4) |
Tegafur/uracil | 0 (0.0) | 1 (2.4) | 0 (0.0) |
Ramucirumab | 0 (0.0) | 0 (0.0) | 3 (7.1) |
Everolimus | 0 (0.0) | 0 (0.0) | 1 (2.4) |
Pegargiminase | 0 (0.0) | 0 (0.0) | 1 (2.4) |